MicroBiopharm Japan

Tokyo, Japan Founded: 2011 • Age: 15 yrs Acquired By Gujarat Themis Biosyn
Contract research and discovery services are provided to biopharma firms.

About MicroBiopharm Japan

MicroBiopharm Japan is a Healthcare company based in Tokyo (Japan) founded in 2011, and was acquired by Gujarat Themis Biosyn in May 2026. Contract research and discovery services are provided to biopharma firms. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Bioreactors.

Company details

MicroBiopharm Japan was founded in 2011 and is based in Tokyo, Japan. Contract research services are offered to biopharma companies, focusing on fermentation, strain development, and process optimization. Drug discovery is supported through libraries of microorganisms, P450 compounds for hydroxylation, and vitamin D derivatives. The portfolio encompasses anthracycline analogs, macrolide analogs, calcitriol, paricalcitol, pipecolic acid analogs, vitamin D analogues, and cyclodextrins within the biotechnology sector.

Key Metrics

Funding Insights of MicroBiopharm Japan

  • Total Rounds 1
  • Investors Count 1

All 1 funding rounds of MicroBiopharm Japan with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jan 2011Seed–Toray Industries
–
Valuation history

2 investors in total: 2 institutional.

Investors in MicroBiopharm Japan

MicroBiopharm Japan has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Toray and Gujarat Themis Biosyn.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Manufacturer of Fibers, plastics, composite materials, optical fibers, resins for 3D printing
1926toray.comTokyo, Japan
Application development services are provided from Vapi, India.
1981gtbl.inVapi, India
Premium access

Investor details for MicroBiopharm Japan

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Timeline of MicroBiopharm Japan

3 dated milestones of MicroBiopharm Japan across 15 years, from founding to its latest funding, stage changes and deals.

  1. Founded MicroBiopharm Japan is founded.
  2. Funding First funding round.
  3. Exit Acquired by Gujarat Themis Biosyn.

Web traffic of MicroBiopharm Japan

The website of MicroBiopharm Japan (microbiopharm.com) receives about 1.6K visits a month and ranks #7,946,588 among all websites worldwide, #7,199 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    1.6K

    ▼ 16% vs previous month

  • Global rank
    #7,946,588

    among all websites

  • Category rank
    #7,199

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with MicroBiopharm Japan. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
bioteclab.co.jp
bioteclab.co.jp
100%
#5,470,117–
carnabio.com
92%
21.3K#1,167,012View details
oncolys.com
92%
32.2K#685,223View details
digital-biology.co.jp
digital-biology.co.jp
91%
#1,424,425–
jba.or.jp
91%
#1,337,186View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 13 similar websites and full traffic analytics for MicroBiopharm Japan

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 13 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Microbiopharm Japan

Premium access

Complete news archive for MicroBiopharm Japan

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about MicroBiopharm Japan

MicroBiopharm Japan was founded in 2011.

MicroBiopharm Japan is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.

MicroBiopharm Japan was founded in 2011 and is based in Tokyo, Japan. Contract research services are offered to biopharma companies, focusing on fermentation, strain development, and process optimization. Drug discovery is supported through libraries of microorganisms, P450 compounds for hydroxylation, and vitamin D derivatives. The portfolio encompasses anthracycline analogs, macrolide analogs, calcitriol, paricalcitol, pipecolic acid analogs, vitamin D analogues, and cyclodextrins within the biotechnology sector.

MicroBiopharm Japan has 2 investors. Key investors include Toray, and Gujarat Themis Biosyn.

Yes. MicroBiopharm Japan was acquired by Gujarat Themis Biosyn in May 2026.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available